1. Optical Biometry Derived Axial Length Measurements Following Intravitreal Anti-Vascular Endothelial Growth Factor Treatment for Macular Edema.
- Author
-
Kymionis GD, Giarmoukakis A, Apostolidi IK, Blazaki SV, Tsoulnaras KI, Moschandrea J, Panagopoulou S, and Tsilimbaris MK
- Subjects
- Aged, Angiogenesis Inhibitors administration & dosage, Female, Fluorescein Angiography, Fundus Oculi, Humans, Intravitreal Injections, Macular Edema drug therapy, Macular Edema physiopathology, Male, Prospective Studies, Tomography, Optical Coherence, Visual Acuity, Axial Length, Eye diagnostic imaging, Biometry methods, Macula Lutea pathology, Macular Edema diagnosis, Ranibizumab administration & dosage, Vascular Endothelial Growth Factor A antagonists & inhibitors
- Abstract
Purpose: To evaluate axial length (AL) alterations in patients with macular disease over the course of intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment., Methods: In this prospective, comparative study, 33 patients with macular edema underwent unilaterally intravitreal anti-VEGF therapy and were followed for two months; the contralateral eyes were considered as controls. Central retinal thickness (CRT) was measured with spectral-domain optical coherence tomography and AL with an IOL-Master optical biometer., Results: CRT of the treated eyes decreased by 35.33 ± 65.59 μm (range, -222.00-67 μm), while AL increased by 0.008 ± 0.062 mm (range, -0.11-0.18 mm). CRT of the control group decreased by 9.82 ± 65.40 μm (range, -203-182 μm), and AL increased by 0.011 ± 0.129 mm (range, -0.20-0.67 mm). No significant correlation was detected between CRT and AL parameters (rhos=0.026, P=0.882)., Conclusions: Anti-VEGF administration has no significant impact on optical biometry-derived AL measurements.
- Published
- 2018
- Full Text
- View/download PDF